HUM stock forecast, quote, news & analysis

Key Takeaways

• Humana shares have surged from a 52-week low of $163.11 to roughly $389, marking a powerful recovery driven by improving Medicare Advantage fundamentals and moderating medical cost trends.
• Wells Fargo upgraded HUM to Overweight with a $502 price target in mid-July, citing significantly reduced earnings risk and expectations of meaningful margin progress in 2027.
• Q1 2026 adjusted EPS of $10.31 beat consensus estimates, with revenue of $39.65 billion also topping expectations, affirming the company's full-year adjusted EPS guidance of at least $9.00.
• CenterWell Senior Primary Care added 110,500 patients sequentially, while state-based Medicaid contracts grew membership by approximately 50,000, reflecting expansion beyond traditional Medicare Advantage.
• Q2 2026 earnings are confirmed for July 29, with analysts watching for updated medical cost trends, membership figures, and 2027 benefit design signals.

Current Market Snapshot

Humana Inc. (HUM) closed at $389.32 on July 24, 2026, reflecting a modest gain of approximately 1.4% over the trailing 30-day period. While short-term price action has been relatively contained, the broader context is far more compelling: the stock has mounted an extraordinary rally from its 52-week low of $163.11, more than doubling in value. The 50-day moving average sits near $364, and the 200-day moving average hovers around $265, underscoring the sustained upward momentum. With a market capitalization of roughly $46.7 billion and institutional ownership exceeding 92%, Humana remains one of the most closely watched names in the managed care sector. The stock currently trades well above the consensus analyst price target of approximately $327, suggesting that Wall Street targets have been scrambling to catch up with the rally — and the recent wave of upward revisions reflects growing confidence in the company's margin recovery narrative.

Humana (HUM) Business Overview and Competitive Position

Humana Inc., headquartered in Louisville, Kentucky, is one of the largest health insurance providers in the United States, best known for its dominant position in the Medicare Advantage market. The company serves millions of members through Medicare Advantage plans, stand-alone prescription drug (Part D) coverage, Medicaid managed care, and commercial group health insurance. Beyond traditional insurance, Humana has built a significant healthcare services platform under the CenterWell brand, encompassing primary care clinics, pharmacy services, and home health operations. This integrated care delivery model — combining insurance with direct patient care — differentiates Humana from many peers and positions it to capture value across the healthcare continuum. The company's strategic focus on the rapidly growing senior population, disciplined pricing, and expanding value-based care capabilities gives it a durable competitive moat. Key competitors include UnitedHealth Group (UNH), Cigna (CI), Centene (CNC), and CVS Health (CVS).

Recent Developments Driving HUM

Several meaningful catalysts have shaped investor sentiment around Humana in recent weeks. On July 13, Wells Fargo analyst Stephen Baxter upgraded HUM to Overweight from Equal Weight and raised the price target to $502 from $227, arguing that moderating Medicare Advantage cost trends significantly decrease earnings risk and that Humana's margins should make meaningful progress in 2027 as the company reduces benefits. This upgrade followed other positive analyst actions: Truist raised its target to $415, TD Cowen lifted its target to $350, and Cantor Fitzgerald increased its target to $300 after noting favorable Medicaid enrollment data. On the operational front, Humana secured a major Illinois Medicaid contract covering approximately 3.1 million members across 102 counties through HealthChoice Illinois, expanding its state-based footprint. Additionally, the CenterWell segment continues to scale rapidly — sequential patient growth of 110,500 in Senior Primary Care, fueled partly by the MaxHealth acquisition, highlights the company's push into payor-agnostic care delivery. The company also completed a $276 million share repurchase program and maintained its dividend, signaling confidence in its balance sheet. Network developments, including the reported termination of an agreement with Ohio State's Wexner Medical Center, represent areas for investors to monitor but have not derailed the broader positive thesis.

Trending AI Robots

For traders seeking data-driven signals in stocks like Humana, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI-powered trading bots. Tickeron hosts hundreds of algorithmic trading bots that trade thousands of tickers across various strategies, timeframes, and performance benchmarks, but only the most relevant and consistently strong performers appear in the Trending section. These bots employ diverse approaches — from short-term momentum plays to longer-duration swing trading models — and each bot displays transparent historical performance metrics, trade counts, and win rates. For investors monitoring the healthcare and managed care space, the Trending AI Robots page can serve as a useful screen for identifying which strategies are currently generating alpha in this evolving market environment.

2026 Outlook and What Investors Should Watch

Looking ahead, Humana's investment narrative hinges on several decisive factors. The upcoming Q2 2026 earnings report on July 29 is the most immediate catalyst: analysts expect EPS around $6.17 to $7.23, and any deviation in the medical loss ratio, membership growth, or forward commentary on 2027 benefit design will be scrutinized closely. The company has set a target of returning to a sustainable individual Medicare Advantage margin of at least 3% by 2028, with meaningful progress expected in 2027. Key variables include the trajectory of medical cost trends — which have shown signs of moderation — and the company's bidding strategy for the 2027 plan year. Star Ratings recovery remains a critical watchpoint, as higher quality scores directly impact bonus payments and rebate dollars. CenterWell's ability to sustain its growth trajectory and improve operating margins will test the thesis that integrated care delivery can offset insurance margin pressure. On the regulatory front, any changes to Medicare Advantage reimbursement rates, risk adjustment methodology, or Medicaid redetermination policies could reshape the industry landscape. With analysts forecasting EPS recovery to approximately $15 in 2027 from roughly $9 in 2026, execution on the margin recovery roadmap will determine whether the stock's impressive rally has further room to run.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations